Clinical Trial Update: Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD [NA]

View source ↗

Summary

This ClinicalTrials.gov listing describes an ongoing trial investigating adaptive therapy for patients with resected stage I A2 to II non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: NSCLC | NA | Status: RECRUITING